Every Form 4 that Vertex Pharmaceuticals Inc (VRTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRTX filings page.
Vertex Pharmaceuticals director Bruce I. Sachs reported an automatic grant of deferred stock units tied to his board service. On January 15, 2026, he acquired 107.088 deferred stock units at a reference price of $443.56 per unit, bringing his total to 15,564.521 deferred stock units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock at the earliest of Sachs leaving the board, a change of control of the company, or his disability or death. This filing reflects equity-based compensation rather than an open-market stock purchase or sale.
Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported selling 4,500 shares of Vertex common stock on 01/07/2026 at a price of $474.99 per share. After this transaction, she beneficially owned 42,293 shares, all held directly.
The filing notes that the sale was made pursuant to Dr. Tatsis’ company-approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. Such plans are pre-arranged programs that allow insiders to sell stock according to preset terms, helping them diversify holdings while addressing concerns about trading on material nonpublic information.
Vertex Pharmaceuticals executive Charles F. Jr. Wagner, EVP, CO & FO, reported an option exercise and share sale in company stock. On 01/06/2026 he exercised 9,532 stock options at an exercise price of $189.38 per share, receiving the same number of Vertex common shares. That same day, he sold 9,532 common shares at a price of $461 per share, a transaction coded as a sale. After these transactions, he directly owned 37,725 shares of Vertex common stock. The filing notes that the sale was made under Mr. Wagner’s company-approved Rule 10b5-1 trading plan, which was entered into on 05/09/2025, and that the exercised options were fully vested.
Vertex Pharmaceuticals' EVP, CO & FO reported pre-planned stock sales under a Rule 10b5-1 trading plan. On 12/03/2025, the officer sold 7,000 shares of Vertex common stock at $451 per share and another 7,000 shares at $461 per share, both reported as open-market sales. These transactions were made pursuant to a company-approved Rule 10b5-1 trading plan that Mr. Wagner entered into on 5/9/2025. After the reported sales, he beneficially owned 37,725 shares of Vertex common stock directly.
Vertex Pharmaceuticals executive Dr. Ourania Tatsis reported an open market sale of company stock. On 12/03/2025, she sold 4,500 shares of Vertex common stock at a weighted average price of $449.99 per share, with individual sale prices ranging from $449.99 to $450.00. The transaction was coded as an open market sale and was made under a company-approved Rule 10b5-1 trading plan that Dr. Tatsis entered into on 08/21/2025. After this sale, she beneficially owned 46,793 shares of Vertex common stock directly.
A director of Vertex Pharmaceuticals (VRTX) reported a change in ownership of the company’s common stock. On 11/19/2025, the director recorded a transaction in which 800 shares of Vertex common stock were disposed of, coded as transaction type “G”. The shares were reported at a price of $0, indicating no cash consideration was recorded for this movement of shares in the form.
After this transaction, the director beneficially owns 6,315 shares of Vertex common stock in direct ownership. The filing is made on Form 4, which is used to report changes in insider ownership for directors, officers, and significant shareholders.
Vertex Pharmaceuticals (VRTX) executive Mark Atkinson reported a planned stock sale. As Executive Vice President and Chief Technical Operations Officer, he filed a Form 4 showing the sale of 2,500 shares of Vertex common stock on 11/17/2025 at a price of $434.58 per share.
After this transaction, he beneficially owned 16,852 shares directly. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on 08/11/2025, meaning the trades were pre-arranged under SEC rules designed to allow insiders to sell shares according to a preset plan.
Vertex Pharmaceuticals (VRTX) reported insider transactions by its Executive Chairman and Director, Dr. Jeffrey Leiden. On 11/13/2025 and 11/14/2025, he exercised stock options to acquire Vertex common stock at exercise prices of $91.05 and $86.52 per share, then sold portions of the shares in the open market.
Reported sales included 18,528 shares at a weighted average price of $440.22, 1,160 shares at $441.05, 32,234 shares at $440.30, and 21,330 shares at $441.35, plus smaller additional amounts. After these transactions, Dr. Leiden beneficially owned 24,026 Vertex shares directly and 440 shares through a 401(k), along with vested stock options. The filing notes the trades were made under a company-approved Rule 10b5-1 trading plan entered into on 8/6/2025.